You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for New Drug Application (NDA): 207131


✉ Email this page to a colleague

« Back to Dashboard


NDA 207131 describes CEFAZOLIN IN DEXTROSE, which is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. It is available from one supplier. Additional details are available on the CEFAZOLIN IN DEXTROSE profile page.

The generic ingredient in CEFAZOLIN IN DEXTROSE is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.
Summary for 207131
Tradename:CEFAZOLIN IN DEXTROSE
Applicant:Baxter Hlthcare Corp
Ingredient:cefazolin sodium
Patents:0
Pharmacology for NDA: 207131
Medical Subject Heading (MeSH) Categories for 207131
Anti-Bacterial Agents
Suppliers and Packaging for NDA: 207131
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEFAZOLIN IN DEXTROSE cefazolin sodium SOLUTION;INTRAVENOUS 207131 NDA Baxter Healthcare Corporation 0338-0096 0338-0096-06 6 BAG in 1 CARTON (0338-0096-06) / 150 mL in 1 BAG
CEFAZOLIN IN DEXTROSE cefazolin sodium SOLUTION;INTRAVENOUS 207131 NDA Baxter Healthcare Corporation 0338-3503 0338-3503-41 24 BAG in 1 CARTON (0338-3503-41) / 50 mL in 1 BAG

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 2GM BASE/100ML (EQ 20MG BASE/ML)
Approval Date:Aug 7, 2015TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 1GM BASE/50ML (EQ 20MG BASE/ML)
Approval Date:Feb 1, 2021TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 3GM BASE/150ML (EQ 20MG BASE/ML)
Approval Date:May 31, 2024TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links